The quality of evidence was judged by using the Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence that ranges from Level 1 to Level 5 based on the quality and study design. The search resulted in 23 relevant studies on CBD and nabiximols in the treatment of a wide range of psychiatric disorders. Materials and methodĪ systematic review was conducted including case reports, case series, open-label trials, non-randomized and randomized controlled trials (RCTs). that has been purified into 1:1 ratio of CBD and delta-9-tetrahydrocannabinol) in the treatment of psychiatric disorders. To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use.
0 Comments
Leave a Reply. |